This compendium of facts and figures relating to the biopharmaceutical industry and global health aims to provide a snapshot of the work this industry undertakes today.
Read more13 September 2022, Tel Aviv, Israel – IFPMA and GSCF welcome the opportunity to provide comments and share insights from our Covid-19 Lessons Learned report, , which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility are among the lessons that must be preserved for future ability to fight against...
Read moreAhead of the Global Fund Seventh Replenishment for 2024-2026, the innovative biopharmaceutical industry reaffirms its longstanding commitment to support the Global Fund mission to defeat HIV, TB, and malaria, and ensure a healthier, safer, more equitable future for all.
Read moreLeveraging the power of collaboration to end HIV, tuberculosis, and malaria.
Read moreViruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose.
Read moreIFPMA is delighted to be able to join this SEARO Regional Committee meeting and appreciates the opportunity to make this statement
Read moreIFPMA welcomes the opportunity to comment on the WHO AFRO region’s strategy for health security and emergencies. The innovative biopharmaceutical industry is keen to learn lessons from the COVID-19 pandemic and to work with others to ensure we are much better prepared for the next health emergency. We are not surprised by the assessment from...
Read morePrepared for IFPMA, Airfinity have authored a report detailing the COVID-19 pandemic in Africa, with a key focus on vaccinations.
Read moreThis infographic provides an overview of the status of COVID-19 vaccines in Africa, outlining issues of inequitable distribution on the continent, factors contributing to this, and policy recommendations to ensure equitable access to vaccines in future.
Read moreWe congratulate you on the early progress made on this important and complex work. We will share written comments in due course. At a high level, we welcome the recognition that the development of new medicines rests on the protection of intellectual property rights; that our ability to develop medical countermeasures relies on unhindered and...
Read moreThe innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics. In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics...
Read moreThe biopharmaceutical industry launched today the “Berlin Declaration – biopharmaceutical industry vision for equitable access in pandemics” and presents global leaders with a proposal that could help ensure the supply of pandemic vaccines, treatments and diagnostics are delivered as early as possible in future pandemics to those who need them most.
Read more